Krishna Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.75 M
as on 22-06-2024
- Paid Up Capital ₹ 0.75 M
as on 22-06-2024
- Company Age 30 Year, 7 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 5.36 Cr
as on 22-06-2024
- Satisfied Charges ₹ 1.90 M
as on 22-06-2024
- Revenue %
(FY 2020)
- Profit -101.40%
(FY 2020)
- Ebitda 8.08%
(FY 2020)
- Net Worth -3.28%
(FY 2020)
- Total Assets 38.62%
(FY 2020)
About Krishna Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.75 M and a paid-up capital of Rs 0.75 M.
The company currently has active open charges totaling ₹5.36 Cr. The company has closed loans amounting to ₹1.90 M, as per Ministry of Corporate Affairs (MCA) records.
Veena Jain and Rakesh Jain serve as directors at the Company.
- CIN/LLPIN
U24231UP1994PTC016372
- Company No.
016372
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Apr 1994
- Date of AGM
30 Sep 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Muzaffarnagar, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Krishna Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Veena Jain  | Director | 26-Apr-1994 | Current |
| Rakesh Jain | Director | 26-Apr-1994 | Current |
Financial Performance of Krishna Pharmaceuticals.
Krishna Pharmaceuticals Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 101.4% decrease in profit. The company's net worth dipped by a decrease of 3.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Krishna Pharmaceuticals?
In 2020, Krishna Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Overseas Bank Creation Date: 02 Apr 2009 | ₹5.36 Cr | Open |
Indian Oversease Bank Creation Date: 12 Oct 2001 | ₹0.50 M | Satisfied |
Indian Oversease Bank Creation Date: 12 Oct 2001 | ₹0.90 M | Satisfied |
How Many Employees Work at Krishna Pharmaceuticals?
Unlock and access historical data on people associated with Krishna Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Krishna Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Krishna Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
